2026 MaTOS GU | Session III | Challenging Urothelial Carcinoma Cases
Overview
Case 1: Dr. Grivas presented a 49M with T1 high-grade bladder cancer. Panel stressed germline testing, BCG vs IO tradeoffs, shortages, and need for better intravesical trials.
Case 2: Dr. Tripathi presented a 54M with variant urothelial cancer; panel favored EV+pembro neoadjuvant, stressed PET/ctDNA monitoring, pathology accuracy, and cystectomy debate.
Case 3: Dr. Sonpavde presented a 65M with renal pelvis cancer: panel stressed staging, neoadjuvant chemo+IO, surgery, germline testing, and emerging roles for EV+pembro and utDNA.
Case 4: Dr. Bellmunt presented a metastatic UC case: post-chemo, ctDNA− but lung mets found; panel debated adjuvant IO vs observation, noting ctDNA limits and need for better biomarkers.
Case 2: Dr. Tripathi presented a 54M with variant urothelial cancer; panel favored EV+pembro neoadjuvant, stressed PET/ctDNA monitoring, pathology accuracy, and cystectomy debate.
Case 3: Dr. Sonpavde presented a 65M with renal pelvis cancer: panel stressed staging, neoadjuvant chemo+IO, surgery, germline testing, and emerging roles for EV+pembro and utDNA.
Case 4: Dr. Bellmunt presented a metastatic UC case: post-chemo, ctDNA− but lung mets found; panel debated adjuvant IO vs observation, noting ctDNA limits and need for better biomarkers.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Speakers and Panelists:
Ashish M. Kamat, MD, MBBS (Presented by Petros Grieves, MD, PhD)
Abhishek Tripathi, MD
Guru Sonpavde, MD
Joaquim Bellmunt, MD, PhD
Peter H. O’Donnell, MD
Date of Release
March 20th, 2026
%2016.47.03-1770752981975.webp&w=3840&q=75)
